Skip to content

About Us:

Foundation News


About Us: Foundation News

The Spinal Muscular Atrophy Foundation Rings Nasdaq Opening Bell

August 18, 2018

The Spinal Muscular Atrophy (SMA) Foundation, a non-profit, organization whose mission is to accelerate the development of treatments for SMA, the leading cause of genetic death in young children, visited the Nasdaq MarketSite in Times Square on August 17, 2018. In honor of the occasion, Dinakar Singh, Co-Founder and Chairman of the Board of Directors,…

Read More

Central and Peripheral Treatment of SMA meeting summary

November 20, 2017

On November 10th, the SMA Foundation held a meeting with over 100 SMA researchers, clinicians, and patient advocacy group representatives to discuss the potential impact of SMN upregulation outside of the central nervous system (CNS). The meeting focused on evidence from preclinical models and patients that indicate SMN has a role outside of the CNS…

Read More

President Obama Signs into Law The Food and Drug Administration Safety and Innovation Act (FDASIA)

July 10, 2012

On July 9, 2012, President Obama signed into law The Food and Drug Administration Safety and Innovation Act (FDASIA), S. 3187. In their news release, the EveryLife Foundation for Rare Diseases highlights a key aspect of this legislation as pertinent to SMA drug development —  it will “empower [the] FDA to use all the science…

Read More

The Spinal Muscular Atrophy Foundation Announces the Publication of Results from the Biomarkers for SMA (BforSMA) Clinical Study

May 4, 2012

NEW YORK, NY | May 4, 2012 – The Spinal Muscular Atrophy (SMA) Foundation congratulates the members of the Pilot Study of Biomarkers for Spinal Muscular Atrophy (BforSMA) Trial Group for the recent publication of study results in two articles published by the open-access, peer-reviewed journal, PLoS ONE. The goal of the BforSMA study was…

Read More

The Spinal Muscular Atrophy Foundation Announces a Biomarker Panel to Guide SMA Therapeutic Development

April 3, 2012

NEW YORK, NY | April 3, 2012 – The Spinal Muscular Atrophy (SMA) Foundation announced today the launch of a biomarker assay panel for SMA using Myriad RBM’s Multi-Analyte Profiling (MAP) technology platform. The SMA-MAP panel is designed to evaluate the severity of SMA and disease progression and can be used to assess drug efficacy…

Read More

NORD Supports FAST Act Introduced by Representatives Stearns and Towns

March 9, 2012

Two bills have been introduced in Congress which are intended to expedite the drug approval process for diseases with serious unmet medical need such as SMA. On February 15, 2012, the Transforming the Regulatory Environment to Accelerate Access to Treatments (TREAT) Act, S. 2113, was introduced by Senator Kay Hagan (D-NC) and on March 5, 2012…

Read More

SMA Foundation Observes Rare Disease Day

February 21, 2012

New York, NY, February 21, 2012 – The Spinal Muscular Atrophy (SMA) Foundation will join the National Organization for Rare Disorders (NORD) and others around the world in observing Rare Disease Day on February 29.  The purpose is to focus attention on the needs of patients and families affected by rare diseases. “This is a…

Read More

Roche, PTC & SMA Foundation Agreement to Develop a Treatment for SMA Receives Extensive Coverage

February 13, 2012

On November 29, 2011, Roche, PTC Therapeutics and the SMA Foundation announced the signing of an agreement to develop a treatment for Spinal Muscular Atrophy. Several media sources reported on the agreement including BioCentury, BioWorld Today, Bloomberg Businessweek, Chemical & Engineering News, Clinical Professionals, Dow Jones VentureWire, Drug Discovery News, FierceBiotech, Genetic Engineering and Biology News,…

Read More

Isis Initiates Phase 1 Clinical Study of ISIS-SMNRx in Patients with Spinal Muscular Atrophy

December 19, 2011

CARLSBAD, Calif., December 19, 2011 – Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated a Phase 1 study of ISIS-SMNRx in patients with spinal muscular atrophy (SMA). SMA is a severe motor-neuron disease that is the leading genetic cause of infant mortality. Isis is developing ISIS-SMNRx as a potential treatment for all…

Read More

Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)

November 29, 2011

Collaboration offers new hope for a potential treatment for the leading genetic cause of death in infants and toddlers Basel, Switzerland, South Plainfield, NJ, USA and New York, NY, USA – November 29, 2011 – Roche (SIX: RO, ROG; OTCQX: RHHBY), PTC Therapeutics, Inc. (PTC) and the SMA Foundation, announced today a licensing agreement for…

Read More

Congratulations to Stephen Mikita, Esq., on his new role as a Patient Representative to the FDA

November 23, 2011

Congratulations to SMA Foundation Board Member, Stephen Mikita, Esq., on his new role as a Patient Representative to the U.S. Food and Drug Administration (FDA). Mr. Mikita recently completed the Patient Representative training program with the FDA’s Office of Special Health Issues. As a Patient Representative, Mr. Mikita will participate in advisory committees to review…

Read More

Save the Date – SfN 2011

September 9, 2011

Save the Date – Society for Neuroscience 2011 Monday November 14, 2011 6:30 – 9:30 p.m. Washington Convention Center, 150B Pretzels and endplates: Motor neuron pathology and the role of SMN in motor neuron development Chien-Ping Ko, PhD, University of Southern California “Synaptic defects in the spinal and neuromuscular circuitry in SMA” George Mentis, PhD,…

Read More
Scroll To Top